APTORUM GROUP LTD-CLASS A (APM)
KYG6096M1226 - Common Stock
We assign a fundamental rating of 2 out of 10 to APM. APM was compared to 586 industry peers in the Biotechnology industry. APM may be in some trouble as it scores bad on both profitability and health. APM is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year APM has reported negative net income.
In the past year APM has reported a negative cash flow from operations.
APM had negative earnings in 4 of the past 5 years.
APM had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -13.69%, APM belongs to the top of the industry, outperforming 86.67% of the companies in the same industry.
With an excellent Return On Equity value of -11.37%, APM belongs to the best of the industry, outperforming 89.57% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.69% | ||
| ROE | -11.37% | ||
| ROIC | N/A |
ROA(3y)-58.32%
ROA(5y)-47.75%
ROE(3y)-59.95%
ROE(5y)-55.8%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
APM's Gross Margin of 2.45% is fine compared to the rest of the industry. APM outperforms 74.02% of its industry peers.
APM's Gross Margin has declined in the last couple of years.
APM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 2.45% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-33.2%
2. Health
2.1 Basic Checks
APM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, APM has more shares outstanding
Compared to 5 years ago, APM has less shares outstanding
The debt/assets ratio for APM has been reduced compared to a year ago.
2.2 Solvency
APM has an Altman-Z score of -9.89. This is a bad value and indicates that APM is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of APM (-9.89) is worse than 77.61% of its industry peers.
APM has a Debt/Equity ratio of 0.13. This is a healthy value indicating a solid balance between debt and equity.
APM has a worse Debt to Equity ratio (0.13) than 65.30% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.13 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -9.89 |
ROIC/WACCN/A
WACC7.86%
2.3 Liquidity
A Current Ratio of 1.18 indicates that APM should not have too much problems paying its short term obligations.
The Current ratio of APM (1.18) is worse than 87.01% of its industry peers.
A Quick Ratio of 1.18 indicates that APM should not have too much problems paying its short term obligations.
APM has a Quick ratio of 1.18. This is amonst the worse of the industry: APM underperforms 85.98% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.18 | ||
| Quick Ratio | 1.18 |
3. Growth
3.1 Past
APM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 66.81%, which is quite impressive.
The Revenue for APM has decreased by -66.82% in the past year. This is quite bad
Measured over the past years, APM shows a small growth in Revenue. The Revenue has been growing by 2.57% on average per year.
EPS 1Y (TTM)66.81%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q123.1%
Revenue 1Y (TTM)-66.82%
Revenue growth 3Y-22.03%
Revenue growth 5Y2.57%
Revenue growth Q2Q-100%
3.2 Future
APM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 262.38% yearly.
APM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 96.87% yearly.
EPS Next Y86.79%
EPS Next 2Y262.38%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year9197.28%
Revenue Next 2Y347.73%
Revenue Next 3Y145.13%
Revenue Next 5Y96.87%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
APM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for APM. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as APM's earnings are expected to grow with 262.38% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y262.38%
EPS Next 3YN/A
5. Dividend
5.1 Amount
APM does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
APTORUM GROUP LTD-CLASS A
NASDAQ:APM (5/17/2024, 7:00:01 PM)
4.75
-0.35 (-6.86%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap25.98M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.69% | ||
| ROE | -11.37% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 2.45% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.13 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.18 | ||
| Quick Ratio | 1.18 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)66.81%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y86.79%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-66.82%
Revenue growth 3Y-22.03%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y